Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-1386 in relapsed or refractory solid tumors
NCT05361954Phase 1Not yet recruiting
- Sponsor
- Sorrento Therapeutics
- Start
- Aug 2023
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
Phase 1, open-label, single-arm trial of seprehvec in solid tumor, pancreatic cancer (PC), soft tissue sarcoma (STS) and 1 more, sponsored by Sorrento Therapeutics. Primary endpoints: Incidence of adverse events (AEs) and Incidence of immune-related adverse events (IrAEs). Planned start Aug 2023; status: not yet recruiting.
02
Drugs
seprehvec
03
Conditions
solid tumorpancreatic cancer (PC)soft tissue sarcoma (STS)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05361954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361954.